N-methyl-trans-decahydroquinoline | 875-63-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉类
• 英文名称: N-methyl-trans-decahydroquinoline
• 英文别名: N-Methyl-trans-decahydrochinolin；1-Methyl-trans-decahydro-chinolin；1-Methyl-trans-decahydrochinolin；N-Methyl-trans-decahydrochinolin；N-Methyl-trans-perhydrochinolin；N-Methyl-decahydrochinolin；Quinoline, decahydro-1-methyl-, trans-；(4aR,8aS)-1-methyl-3,4,4a,5,6,7,8,8a-octahydro-2H-quinoline
• CAS: 875-63-8
• 化学式: C₁₀H₁₉N
• 分子量: 153.268
• InChiKey: AAARTTJTRNAYHQ-ZJUUUORDSA-N

物化性质

• 沸点：
  204-205 °C
• 密度：
  0.904±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-(N,N,N-三甲基氨基)丙基溴 、 N-methyl-trans-decahydroquinoline 生成 (+/-)-1ξ-methyl-1ξ-(3-trimethylammonio-propyl)-(4ar,8at)-decahydro-quinolinium; dibromide
  参考文献：
  名称：

  Bis-ammonium Salts. Unsymmetric Derivatives of Decahydroquinoline and of Decahydroisoquinoline

  摘要：

  DOI：

  10.1021/ja01512a053
• 作为产物：
  描述：

  potassium methyl sulfate 、 (4aR,8aR)-decahydroquinoline 在 水 作用下， 生成 N-methyl-trans-decahydroquinoline
  参考文献：
  名称：

  Bamberger; Williamson, Chemische Berichte, 1894, vol. 27, p. 1470

  摘要：

  DOI：

文献信息

• [EN] AMIDO-THIOPHENE COMPOUNDS AND THEIR USE AS 11-BETA-HSD1 INHIBITORS<br/>[FR] COMPOSÉS AMIDO-THIOPHÈNE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE 11-BÊTA-HSD1
  申请人：UNIV EDINBURGH

  公开号：WO2009074789A1

  公开（公告）日：2009-06-18

  The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain amido-thiophene compounds that, inter alia, inhibit 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 11β-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11β-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc. Formula (I).

  本发明一般涉及治疗化合物领域。更具体地，本发明涉及某些酰胺噻吩化合物，其中包括抑制11β-羟基类固醇脱氢酶1（11β-HSD1）。本发明还涉及包含这些化合物的药物组合物，以及利用这些化合物和组合物在体外和体内抑制11β-羟基类固醇脱氢酶1；治疗通过抑制11β-羟基类固醇脱氢酶1而得到改善的疾病；治疗代谢综合征，其中包括2型糖尿病和肥胖等疾病，以及相关疾病，包括胰岛素抵抗、高血压、脂质紊乱和心血管疾病，如缺血性（冠状）心脏病；治疗中枢神经系统疾病，如轻度认知障碍和早期痴呆，包括阿尔茨海默病等。公式（I）。
• A Highly Active System for the Metal-Free Aerobic Photocyanation of Tertiary Amines with Visible Light: Application to the Synthesis of Tetraponerines and Crispine A
  作者：Julio Cesar Orejarena Pacheco、Alexander Lipp、Alexander M. Nauth、Fabian Acke、Jule-Philipp Dietz、Till Opatz

  DOI：10.1002/chem.201504845

  日期：2016.4.4

  A highly efficient metal‐free catalytic system for the aerobic photocyanation of tertiary amines with visible light is reported. The use of air as terminal oxidant offers an improved safety profile compared with pure oxygen, the used compact fluorescent lamp (CFL) light sources are highly economical, and no halogenated solvents are required. This system not only proves to be effective for a wide variety

  报道了一种高效的无金属催化体系，用于可见光下叔胺的有氧光致氰化。与纯氧相比，使用空气作为终端氧化剂可提高安全性，所使用的紧凑型荧光灯（CFL）光源非常经济，并且不需要卤化溶剂。该系统不仅证明对多种三烷基胺，药物和生物碱有效，而且显着还使有机染料有史以来最低的催化剂负载量（0.00001 mol％或0.1 ppm）。对获得的α-氨基腈进行了Bruylants反应和C-烷基化/脱氰，以证明复杂分子的后功能化。
• BENZODIOXANE INHIBITORS OF LEUKOTRIENE PRODUCTION FOR COMBINATION THERAPY
  申请人：BYLOCK Lars Anders

  公开号：US20130236468A1

  公开（公告）日：2013-09-12

  The present invention relates to a combination comprising compounds of formula (I): wherein R 1 to R 3 , A, X and n are as defined herein, and an additional active agent. The present invention also relates to pharmaceutical compositions comprising these combinations, and methods of using these combinations to treat various diseases and disorders.

  本发明涉及一种组合物，包括式（I）的化合物： 其中R1至R3，A，X和n如本文所定义，并且另外包括一种活性剂。本发明还涉及包括这些组合物的药物组合物，以及使用这些组合物治疗各种疾病和疾病的方法。
• [EN] 2-MORPHOLINO-4-PYRIMIDONE COMPOUND<br/>[FR] COMPOSE 2-MORPHOLINO-4-PYRIMIDONE
  申请人：MITSUBISHI PHARMA CORP

  公开号：WO2006028290A1

  公开（公告）日：2006-03-16

  A compound represented by the formula (I), an optically active isomer thereof, or a pharmaceutical acceptable salt thereof: wherein X represents CH or N; 1 represents a C1-C12 alkyl; R2 represents a hydrogen atom, or the like; R' represents a C1-C6 alkyl or the like; q represents 0 or an integer of 1 to 7; Y represents a C1-C6 alkyl or the like; p represents 0 or an integer of 1 to 5; R represents a 2,3-dihydroindolyl or the like, which is used for preventive and/or therapeutic treatment of a disease caused by tau protein kinase 1 hyperactivity such as a neurodegenerative diseases (e.g. Alzheimer disease).

  化合物的化学式（I）所代表的化合物，其光学活性异构体，或其药用可接受盐：其中X代表CH或N；1代表C1-C12烷基；R2代表氢原子，或类似物；R'代表C1-C6烷基或类似物；q代表0或1至7的整数；Y代表C1-C6烷基或类似物；p代表0或1至5的整数；R代表2,3-二氢吲哚基或类似物，用于预防和/或治疗由tau蛋白激酶1过度活化引起的疾病，如神经退行性疾病（例如阿尔茨海默病）。
• [EN] AMIDO-THIOPHENE COMPOUNDS AND THEIR USE<br/>[FR] COMPOSÉS AMIDO-THIOPHÈNE ET LEUR UTILISATION
  申请人：UNIV EDINBURGH

  公开号：WO2009112845A1

  公开（公告）日：2009-09-17

  The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain amido-thiophene compounds that, inter alia, inhibit 11 β-hydroxysteroid dehydrogenase type 1 (11 β-HSD1 ). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 11 β-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11 β-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc.

  本发明一般涉及治疗化合物领域。更具体地，本发明涉及某些酰胺-噻吩化合物，其中包括抑制11β-羟基类固醇脱氢酶1（11β-HSD1）的作用。本发明还涉及包含这些化合物的药物组合物，以及使用这些化合物和组合物，在体内和体外，抑制11β-羟基类固醇脱氢酶1；治疗通过抑制11β-羟基类固醇脱氢酶1而得到改善的疾病；治疗代谢综合征，其中包括糖尿病和肥胖等疾病，以及相关疾病，包括胰岛素抵抗、高血压、脂质紊乱和心血管疾病，如缺血性（冠状）心脏病；治疗中枢神经系统疾病，如轻度认知障碍和早期痴呆，包括阿尔茨海默病等。